^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

anti-CD30 CAR T cells

i
Other names: anti-CD30 CAR T cells, CD30-targeted chimeric antigen receptor T cell therapy, CD30-Targeted Genetically-modified Autologous T-cell immunotherapy Injection
Associations
Company:
Wuhan Bio–Raid
Drug class:
CD30-targeted CAR-T immunotherapy
Associations
2years
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30 lymphoma. (PubMed, Exp Hematol Oncol)
Our work demonstrates the combined administration of ASCT and CAR30 T-cell therapy is well-tolerate and highly effective in r/r cHL and ALCL, even in PET-positive or chemorefractory patients who are expected to have inferior outcome after ASCT, although further large-scaled validation in prospective clinical trial is warranted. Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662).
Journal • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase)
|
ALK negative • CD34 positive
|
anti-CD30 CAR T cells
over2years
New P2 trial
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
AiRuiKa (camrelizumab) • anti-CD30 CAR T cells